FDA approves IBS drug for children, Linzess, to treat pediatric IBS-C in patients ages 7 and older with proven safety and efficacy.
The FDA has approved Linzess (linaclotide) for children aged 7 and older with IBS-C, marking the first FDA-approved drug for ...
The new approval that came from the USFDA makes it sure that the Linzess is safe and effective, bringing a sense of relief ...
Pharmaceutical Technology on MSN
Former blockbuster Linzess grows label with paediatric IBS-C approval
"Former blockbuster Linzess grows label with paediatric IBS-C approval" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The FDA expands use of linaclotide to children as young as age 7 years with irritable bowel syndrome with constipation (IBS-C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback